Dyax Corp. (Dyax), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program. It is focused on identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema. The principal focus of Dyax is to identify, develop and commercialize treatments for conditions identified as plasma kallikrein (bradykinin) mediated angioedema, including hereditary angioedema (HAE), ACE inhibitor-induced angioedema (ACEI-AE) and angioedema of unknown origin, or idiopathic angioedema. It developed KALBITOR (ecallantide) on its own in the United States for the treatment of acute attacks of HAE. Outside of the United States, it has established partnerships to obtain regulatory approval for and commercialize KALBITOR in certain markets and it is evaluating opportunities in others. It leverages its phage display technology through the Licensing and Funded Research Program (LFRP).
|Headquarters||55 Network Drive|
BURLINGTON, MA, United States 01803
|Chairman of the Board||Henry Blair|
|President, Chief Executive Officer, Director||Gustav Christensen|
|Chief Financial Officer, Executive Vice President||George Migausky|
|Chief Medical Officer, Executive Vice President - Research and Development||Burt Adelman|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||109.2M||Book Value||$-0.52|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||6.4|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-33.70%|
*GAAP = prior to non-GAAP analyst adjusted earnings.